210O Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)

Authors :: A. Marra
A. Gazzo
A. Gupta
P. Selenica
E.M. Da Silva
F. Pareja
X. Pei
Y. Zhu
P. Razavi
A. Safonov
E. Ferraro
R. Harris
N. Riaz
J.S. Reis-Filho
S. Chandarlapaty
Source :: Annals of Oncology. 33:S632
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Full Text Access

Tools